<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041</h1>

    <table>
      <tr><th>Ticker</th><td>MTVA</td></tr>
      <tr><th>Float</th><td>1.4 M</td></tr>
      <tr><th>IO</th><td>1.59%</td></tr>
      <tr><th>MC</th><td>6.4 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>MetaVia Inc. (NASDAQ: MTVA) announced a global intellectual property portfolio for lead asset DA-1726, comprising 39 granted and pending U.S. and international patents (exclusive license from Dong-A ST Co., Ltd.) providing protection into 2041. DA-1726 is a once-weekly oxyntomodulin (OXM) analogue acting as a dual GLP-1/glucagon receptor agonist for obesity and related metabolic disorders. MetaVia highlighted Phase 1 data at a 48 mg dose showing ~9% weight loss, waist reduction, improved glycemic measures and early liver benefit with a favorable safety profile. The company plans 16-week titration studies to 48 mg and 64 mg with results expected in Q4 2026. MetaVia also referenced its other asset, vanoglipel (DA-1241) for MASH.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Established global patent estate of 39 granted/pending patents covering DA-1726, providing protection into 2041</li><li>Exclusive license to the DA-1726 intellectual property from Dong-A ST Co., Ltd.</li><li>Phase 1 data at 48 mg showing ~9% weight loss, waist reduction, improved blood sugar and early liver benefit with favorable safety profile</li><li>Planned 16-week titration studies to 48 mg and 64 mg with results expected in Q4 2026</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Patent protection currently stated to extend into 2041 but may require extension beyond that date</li><li>Forward-looking statements indicate risks including sufficiency of cash, regulatory approval timelines, and ability to complete clinical trials</li><li>Program and commercial success dependent on license agreement execution and cooperation with contract manufacturers and study partners</li><li>Potential costs or litigation related to the license agreement noted as a risk</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/558ccfc8-98ee-467f-8ee3-8d2f01762e36" target="_blank">Original Article</a>
    </div>

    <div class="small">MTVA â€¢ TradersLink AI News</div>
  </div>
</body>
</html>